Shin-Etsu Chemical Has Developed an Epoch-making Type of Molding Silicone Rubber That Does Not Require Post Cure
28.9.2020 09:00:00 EEST | Business Wire | Press release
In addition to its already being marketed liquid silicone rubber form, Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo, President, Yasuhiko Saitoh) has now developed a molding silicone rubber that also does not require post cure in its millable form.
Shin-Etsu is the first in the industry to have developed a millable (high consistency) type* of silicone rubber that does not require a post cure. Shin-Etsu succeeded in developing this breakthrough product by making use of the unique technology that Shin-Etsu Chemical has cultivated over a long period of years.
In the existing molding method for millable-type silicone rubber, after the initial press cure of the silicone molding is performed, a post cure is carried out in order to drive off the residues that are left within the molded product as a result of the vulcanization agent used in rubber molding as well as the low-molecular siloxane.
Compared to the existing product, the new silicone rubber molding product that Shin-Etsu has developed greatly reduces the amount of low-molecular siloxane content, and by employing an addition-reaction cure system that does not create by-products at the time of a press cure, the process of post cure becomes unnecessary. Because of this, our new product will contribute to molding-makers’ productivity improvements and energy saving, and at the same time, we are expecting that this new product will respond to such customer requests as preventing the adhesion of foreign substances to the molded products.
Furthermore, this new product is suitable for various molding methods such as extrusion molding, transfer molding, calender molding, press molding and injection molding.
With regard to its liquid-type silicone rubber, already ahead of others in the industry, Shin-Etsu Chemical is marketing its LIMS (Liquid Injection Molding System) materials that do not require post cure, and LIMS is being widely used in various fields, mainly for applications in automobile parts.
In September 2017 Shin-Etsu Chemical opened a silicone rubber molding technical center. This Shin-Etsu Molding Technical Laboratory is located in Higashimatsuyama City, Saitama Prefecture, Japan. At this Laboratory a millable injection-molding machine is installed, and we will be carrying out demonstrations there of molding using this new product. Going forward, at this Laboratory we will strive to meet the current and also future requests that are received from our customers by enhancing the technical services we will be able to offer to them.
Silicone rubber combines many superior characteristics such as excellent heat resistance, cold resistance, weatherability and stable electrical insulation properties, all of which are not found in ordinary organic rubber. For this reason, it is used in a wide range of applications such as in automobiles, electric-electronics equipment, OA equipment, home appliances and products for daily use.
Taking advantage of Shin-Etsu Chemical's superior product quality and technological strengths as well as our system for detailed response to our customers' requests, going forward Shin-Etsu will continue to strive to meet the needs of the diversifying market.
* millable type: It involves the use of a mixer, called a “roll mill,” and it is a general term for rubber materials that are being mixed.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200927005079/en/
Contact information
For inquires about this matter, please contact:
Shin-Etsu Chemical Co., Ltd.
Public Relations Dept.
Tetsuya Koishikawa
Tel: 03-3246-5091, or from outside Japan: 81-3-3246-5091
Fax: 03-3246-5096, or from outside Japan: 81-3-3246-5096
e-mail: sec-pr@shinetsu.jp
www.shinetsu.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES and Sky Sign Multi-Year Satellite Capacity Agreement30.9.2026 09:50:00 EEST | Press release
SES and Sky have extended their long-standing partnership in a new multi-year agreement for direct-to-home (DTH) satellite services across the United Kingdom and Republic of Ireland, running into the next decade. Under the agreement, Sky will continue to leverage SES's satellite capacity at the 28.2 degrees East orbital position to deliver television services to millions of households across the region. The renewal extends a partnership that dates to 1988 and reinforces satellite's ongoing role in delivering premium television experiences at scale. “As we give customers more choice in how they access Sky, satellite continues to play an important role in how we deliver our services to customers across the UK and Ireland,” said Nick Herm, Group Chief Operating Officer, Sky. “This agreement with SES provides the reliability, reach and service quality we need to continue delivering the viewing experience our satellite customers expect.” "Sky has been a valued partner of SES for nearly four
rhode Launches at Sephora in Europe, Marking Its First Retail Presence Across 19 New Markets30.9.2026 09:30:00 EEST | Press release
rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), is available starting today, Wednesday, 30 September, 2026, at Sephora online and in over 500 stores across Europe. This expansion with Sephora in Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This follows the 2025 rollout with Sephora in the U.S., Canada, and the U.K. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929500812/en/ rhode launches into Sephora across Europe Launched in June 2022, rhode began with a curated lineup of efficacious skincare, expanding into hybrid makeup. Each launch has garnered tremendous demand, inspiring shifts across the beauty industry and culture at large. Today, rhode is the No. 1 overall skincare brand in the U.S. by EMV and continues to deliver significant year-over-year growth, according to CreatorIQ.* rhode is now available for con
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio ® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis30.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label extension study in adults and adolescents with moderate-to-severe atopic dermatitis’, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, on Thursday, October 1, from 10:45-10:55 AM CET in Hall N by Dr. Matthias Augustin, an ARCADIA clinical trial investigator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929663019/en/ “These three-year data provide important evi
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill30.9.2026 08:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from threePhase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zasocitinib’s superior efficacy compared to deucravacitinib and reinforce the potential for zasocitinib to deliver rapid, durable and consistent skin clearance in a convenient once-daily pill.2-5 “Psoriasis is a heterogeneous disease driven by multiple immune pathways and TYK2 plays a central role in regulating several key inflammatory signals,” said Chinwe Ukomadu, M.D., Ph.D., Senior Vice President and Head, Gastrointestinal & Inflammation Therapeutic Area Unit at Takeda. “Across our Phase 3 trials, zasocitinib demonstrated superiority versus two distinct oral thera
Ant International’s Antom Supports Google Gemini in Expanding Access to AI Service in Asia30.9.2026 07:16:00 EEST | Press release
Google Gemini and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership to make AI tools for learning, creativity and productivity more accessible to users in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929520038/en/ Google AI Plus free trial offers are available in select digital payment and retail channels partnering with A+Rewards in Indonesia, with more markets to follow. Promoting Google AI Plus through AI-powered growth engine The collaboration will leverage A+Rewards, Antom’s digital marketing solution powered by privacy-preserving computing and AI technologies, and its extensive partner network of digital payment apps, e-commerce platforms and lifestyle service providers, to help expand access to Google AI Plus. Integrated into more than 30 leading digital platform partners, A+ Rewards provides in-app entry points where users
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom